Clinical Trial Update: MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

View source ↗

Summary

Clinical trial access program for ruxolitinib in polycythemia vera is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Polycythemia Vera | Status: NO_LONGER_AVAILABLE